Close

Cyfra 21-1

Cytokeratin 19 fragment (Cyfra 21-1) is an intermediate structural filament of cytoskeleton 19, typically associated with non-small cell lung cancer (NSCLC), especially of the squamous cell subtype. Cyfra 21-1 was first approved as a tumor marker by the FDA in 2011 to monitor disease progression in lung cancer patients. Its level of expression at the time of diagnosis correlates with the overall prognosis during treatment. It is also reported to be a potential biomarker for ovarian cancer and squamous cell carcinoma.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue

Continue
CN